Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.04B +2.5% |
| Revenue (ttm) | 377.13M +9.8% |
| Net Income | -23.01M |
| EPS | -0.77 |
| Shares Out | 30.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 347,750 |
| Open | 34.50 |
| Previous Close | 34.50 |
| Day's Range | 32.57 - 34.50 |
| 52-Week Range | 17.72 - 44.28 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 48.20 (+42.65%) |
| Earnings Date | Nov 5, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $48.2, which is an increase of 42.65% from the latest price.
News
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Regional honors in Houston, Arizona and Pittsburgh, national healthcare industry recognition and eight Culture Excellence awards bring Castle's 2026 Top Workplaces honors to 13 FRIENDSWOOD, Texas, Nov...
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas Dermato-Onco2026 analysis supports the test's ability t...
Castle Biosciences price target raised to $52 from $44 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $52 from $44 and keeps a Buy rating on the shares following Q3 beat-and-raise. The firm noted that average…
Castle Biosciences price target raised to $41 from $39 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Castle Biosciences (CSTL) to $41 from $39 and keeps an Outperform rating on the shares. The firm updated its…
Castle Biosciences price target raised to $40 from $35 at KeyBanc
KeyBanc raised the firm’s price target on Castle Biosciences (CSTL) to $40 from $35 and keeps an Overweight rating on the shares. The firm notes the company posted a top-…
Castle Biosciences price target raised to $39 from $38 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Castle Biosciences (CSTL) to $39 from $38 and keeps an Outperform rating on the shares. The firm updated its…
Castle Biosciences reports Q3 adjusted EPS (13c), consensus (35c)
Reports Q3 revenue $102.9M, consensus $92.91M. “Our team delivered another strong quarter, reflecting consistent execution across our portfolio,” said CEO Derek Maetzold. “TissueCypher was a key contr...
Castle Biosciences raises 2026 revenue view to $385M-$395M from $345M-$355M
2026 revenue consensus $374.12M.
Castle Biosciences Earnings Call Transcript: Q3 2026
Q3 revenue rose 24% YoY to $102.9M, led by 47% TissueCypher volume growth, and FY2026 revenue guidance increased to $385M–$395M. Adjusted EBITDA was $12.7M, with positive Adjusted EBITDA expected in FY2026 and FY2027.
Castle Biosciences Earnings release: Q3 2026
Castle Biosciences released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Castle Biosciences Quarterly report: Q3 2026
Castle Biosciences has published its Q3 2026 quarterly earnings report on November 5, 2026.
Castle Biosciences Slides: Q3 2026
Castle Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Castle Biosciences Reports Third Quarter 2026 Results
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million fr...
Castle Biosciences initiated with an Outperform at Mizuho
Mizuho analyst Bradley Bowers initiated coverage of Castle Biosciences (CSTL) with an Outperform rating and $60 price target Castle is a diagnostics company using gene expression profiling and spatial...
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will rel...
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Ca...
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-f...
Castle Biosciences: Study shows TissueCypher test changed management
Castle Biosciences (CSTL) announced the publication of a study showing that its TissueCypher Barrett’s Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Ba...
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication...
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic t...
Castle Biosciences to open new laboratory facility in Scottsdale, Arizona
Castle Biosciences (CSTL) announced the opening of its new laboratory and office facility in Scottsdale, Arizona. The company will commemorate the milestone with a grand opening celebration at the new...
Castle Biosciences to Open New Laboratory Facility in Scottsdale
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Bioscie...
Castle Biosciences management to meet with BTIG
Meeting to be held in the Midwest on September 30 and October 1 hosted by BTIG.